Biocartis Group – pharmaceutical daily

September 13, 2017 Off

Biocartis, Genomic Health bring together their Oncotype DX breast recurrence score test and Idylla platform

By Dino Mustafić

Biocartis and Genomic Health have entered a deal to develop an IVD version of the Oncotype DX Breast Recurrence Score…

May 23, 2017 Off

By Dino Mustafić

Biocartis Group, an innovative molecular diagnostics company, has launched of the Idylla NRAS Mutation Test.

May 10, 2017 Off

By Dino Mustafić

Biocartis Group has appointed Herman Verrelst as its new Chief Executive Officer (CEO), effective as of August 2017.